C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

PURPOSE: Findings from the human epidermal growth factor receptor 2 (HER2) –positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Perez, Edith A., Jenkins, Robert B., Dueck, Amylou C., Wiktor, Anne E., Bedroske, Patrick P., Anderson, S. Keith, Ketterling, Rhett P., Sukov, William R., Kanehira, Kazunori, Chen, Beiyun, Geiger, Xochiquetzal J., Andorfer, Cathy A., McCullough, Ann E., Davidson, Nancy E., Martino, Silvana, Sledge, George W., Kaufman, Peter A., Kutteh, Leila A., Gralow, Julie R., Harris, Lyndsay N., Ingle, James N., Lingle, Wilma L., Reinholz, Monica M.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2011
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3056653/
https://ncbi.nlm.nih.gov/pubmed/21245420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.2125
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items